Tyra Bioscience (TYRA) AI Stock Analysis

• Market Cap: $548.95M
• Dividend Yield: N/A
• Average Volume (3M): 312.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: N/A
• EPS Growth: 6.72%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -1.51
• Shares Outstanding: 53,089,960
• 10 Day Avg. Volume: 238,978
• 30 Day Avg. Volume: 312,296
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $30.25
• Price Target Upside: 194.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Tyra Biosciences reflects typical characteristics of a high-risk, early-stage biotech company with significant investment in R&D and no revenue generation. The technical analysis suggests a bearish trend, and valuation metrics show a focus on future growth over current profitability. The recent board appointment may provide strategic benefits, but its effect on immediate financial performance is uncertain. Overall, the stock is positioned as a speculative investment with potential upside tied to successful research outcomes and eventual revenue generation.

Positive Factors

Clinical Efficacy

TYRA-300 led to an impressive 55% ORR in FGFR3+ mUC patients dosed with >90mg, which is significantly higher than erda's ~35% ORR.

Treatment Accessibility

An oral therapy like TYRA-300 could reduce the need for regular hospital visits, making it a more appealing option for NMIBC patients seeking effective treatments with minimal disruption to their daily lives.

Negative Factors

Clinical Development Risks

Risks include delays in clinical development, negative clinical data, failure to achieve regulatory approval, setbacks with other pipeline assets, and slower-than-anticipated commercial uptake.

Tyra Bioscience Business Overview & Revenue Model

Company Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

How the Company Makes Money

Tyra Bioscience makes money primarily through its research and development activities in oncology therapeutics, which are aimed at bringing novel cancer treatments to market. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on product sales if the drugs are successfully commercialized. Additionally, Tyra Bioscience may secure funding through grants and government programs focused on advancing cancer research. As its drugs progress through clinical trials and potentially receive regulatory approval, the company could also earn revenue from direct sales or licensing agreements.

Tyra Bioscience Financial Statement Overview

Summary

Tyra Bioscience's financials reflect its focus on research and development in the biotechnology sector. The company has zero revenue and increasing losses, typical for investing in future growth. Strong liquidity through cash reserves is offset by reliance on external financing and negative profit margins, indicating a high-risk profile.

Income Statement

Tyra Bioscience has consistently reported zero revenue, which is typical for early-stage biotechnology firms focusing on research and development. The company shows increasing losses over the years, with a notable rise in EBIT and net losses, indicating higher operational expenses. This results in negative profit margins, reflecting the company's developmental stage and need for capital investment.

Balance Sheet

The balance sheet shows strong liquidity with significant cash and short-term investments, outpacing total debt, resulting in negative net debt. The equity ratio is robust, showing a high proportion of assets financed by equity, which is positive for stability. However, the company's negative stockholders' equity in previous years reflects accumulated losses, posing a potential risk.

Cash Flow

Cash flow analysis reveals negative operating cash flow, typical for a company in the R&D phase. The high free cash flow outflow, though concerning, is offset by strong financing cash flow, suggesting reliance on external funding. The absence of revenue growth limits free cash flow growth, highlighting reliance on external capital to sustain operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-353.00K	-296.00K	-140.00K	-47.00K
	EBIT
-104.18M	-79.94M	-58.93M	-26.29M	-9.30M
	EBITDA
-104.18M	-79.59M	-58.63M	-26.15M	-9.25M
	Net Income Common Stockholders
-86.48M	-69.13M	-51.72M	-26.14M	-9.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
341.44M	203.47M	251.21M	302.18M	15.22M
	Total Assets
363.56M	225.86M	266.18M	306.70M	16.01M
	Total Debt
6.22M	6.50M	2.62M	1.18M	142.00K
	Net Debt
-85.74M	-51.51M	-248.59M	-301.00M	-15.08M
	Total Liabilities
20.41M	21.59M	8.35M	4.96M	29.65M
	Stockholders Equity
343.15M	204.26M	-95.70M	301.74M	-13.64M
Cash Flow		Free Cash Flow
-70.44M	-50.91M	-50.84M	-24.41M	-8.07M
	Operating Cash Flow
-69.77M	-50.14M	-50.28M	-23.75M	-7.76M
	Investing Cash Flow
-98.40M	-144.60M	-559.00K	-645.00K	-312.00K
	Financing Cash Flow
202.14M	1.54M	632.00	311.35M	23.43M

Tyra Bioscience Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.28
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Neutral. The current price of 10.28 is above the 20-day moving average (MA) of 8.76, above the 50-day MA of 10.21, and below the 200-day MA of 16.58, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 59.47 is Neutral, neither overbought nor oversold. The STOCH value of 90.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TYRA.

Tyra Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	54 Neutral	$579.12M	―	-41.46%	―	2250.99%	3.52%
Sector *	51 Neutral	$5.35B	3.41	-40.83%	2.89%	18.11%	2.60%
TBPH	48 Neutral	$487.51M	―	-29.04%	―	12.12%	-19.00%
MGTX	46 Neutral	$537.00M	―	-143.48%	―	137.42%	-34.13%
SAGE	42 Neutral	$454.96M	―	-63.37%	―	-52.30%	27.13%
TYRA	38 Underperform	$548.95M	―	-31.60%	―	―	6.72%
MNMD	31 Underperform	$482.77M	―	-68.01%	―	―	26.24%

Tyra Bioscience Corporate Events

Tyra Biosciences Appoints Adele M. Gulfo to Board

Tyra Biosciences announced changes in its Board of Directors on January 28, 2025, with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo. Gulfo brings extensive experience from her roles in major pharmaceutical companies like Sumitomo Pharma America, Mylan, and Pfizer. Her appointment is expected to strengthen Tyra Biosciences’ strategic direction, given her background in commercial and business development in the biopharmaceutical industry. With her appointment, Gulfo will also receive stock options and cash compensation under the company’s director compensation program.